Allogene Therapeutics, Inc. filed an 8-K with the SEC on September 2, 2026, disclosing that Geoffrey Parker, Executive Vice President and Chief Financial Officer, provided notice of his retirement from the company effective November 6, 2026.

Key Highlights

  • CFO retirement notice: Geoffrey Parker notified the company of his retirement on August 31, 2026.
  • Effective date: Parker's retirement from all capacities is effective November 6, 2026.
  • Role: Parker holds the title of Executive Vice President and Chief Financial Officer and serves as principal financial officer.
  • Signed by CEO: The filing was signed by Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer, on September 2, 2026.

Allogene Therapeutics Discloses CFO Departure Planned for November 2026

According to the filing, Geoffrey Parker, who serves as Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (NASDAQ:ALLO), provided formal notice of his retirement on August 31, 2026. The retirement is stated to take effect on November 6, 2026, covering his departure "from the Company in all capacities," as the filing states verbatim.

The disclosure was made under Item 5.02 of Form 8-K, which covers departures and appointments of directors or certain officers. No information was provided in the filing regarding a successor to the CFO role, nor were any reasons given for Parker's retirement decision. The company is headquartered at 210 East Grand Avenue, South San Francisco, California 94080, according to the filing.

The report was signed on behalf of Allogene Therapeutics, Inc. by Zachary Roberts, M.D., Ph.D., in his capacity as President and Chief Executive Officer, and was dated September 2, 2026. The filing contains no forward-looking guidance or additional compensatory arrangement disclosures beyond the retirement notice itself.

What Was Disclosed

The filing disclosed that CFO Geoffrey Parker notified Allogene Therapeutics of his retirement from all roles, effective November 6, 2026. No successor or transition details were included in the filing.